NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine aims to train immune system against lung cancer
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a vaccine designed to help the immune system recognize and attack non-small cell lung cancer. About 30 adults with early or locally advanced lung cancer will receive the vaccine every 3 weeks for 3 doses, with optional yearly boosters for up to 5 years. The goal …
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Olivera Finn • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 15, 2026 18:55 UTC
-
New drug targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis study tests an experimental drug called RMC-6236 in adults with advanced solid tumors like lung, colorectal, and pancreatic cancers that have specific RAS mutations. The goal is to see if the drug is safe and tolerable, and how it works in the body. About 754 participants wi…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 16, 2026 22:06 UTC
-
New hope for hard-to-treat cancers? early trial of IDE892 targets MTAP-deleted tumors.
Disease control Recruiting nowThis early-phase study tests a new drug called IDE892, alone or with other treatments, in people with advanced solid tumors (like lung, stomach, bladder, or pancreatic cancer) that have a specific genetic change called MTAP deletion. The main goals are to check safety and find th…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 16, 2026 22:06 UTC
-
New hope for lung cancer: experimental drug pumitamig takes on pembrolizumab in major trial
Disease control Recruiting nowThis phase 3 study compares a new drug, pumitamig, to the standard treatment pembrolizumab in 750 people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. Participants have not had prior treatment for their advanced cancer. The goal is to se…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 16, 2026 22:05 UTC
-
New drug trial targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BMS-986463 in people with advanced ovarian, uterine, or lung cancer that has spread or cannot be removed by surgery. The main goals are to check safety and find the best dose. About 240 participants will receive the drug, and researc…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 16, 2026 22:05 UTC
-
New drug targets Hard-to-Treat cancers in major trial
Disease control Recruiting nowThis study tests an experimental drug called patritumab deruxtecan (HER3-DXd) in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called HER3 found on many cancer cells. About 740 participants with various cancers (inclu…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 16, 2026 22:04 UTC
-
New hope for advanced cancers: first human trial of TH9619 begins
Disease control Recruiting nowThis early-phase study tests a new drug called TH9619 in people with advanced solid tumors (colorectal, head and neck, lung, or stomach cancer) that have not responded to prior treatment. The main goals are to find a safe dose and check for side effects. About 43 participants wil…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: One-carbon Therapeutics AB • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Could zapping tumors with surgery or radiation extend life in advanced lung cancer?
Disease control Recruiting nowThis study looks at people with stage IV non-small cell lung cancer whose tumors have shrunk with standard treatments like chemo or immunotherapy. Researchers want to see if also treating leftover tumor spots with surgery or radiation helps keep the cancer from growing back longe…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: NA • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New drug combo targets hard-to-treat cancers with KRAS mutation
Disease control Recruiting nowThis study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New drug EXS74539 enters early human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs that the drug sh…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New hope for Drug-Resistant lung cancer: experimental pill enters human trials
Disease control Recruiting nowThis study tests a new oral drug, STX-241, in people with advanced non-small cell lung cancer that has become resistant to standard targeted therapies. The drug is designed to reach the brain and attack cancer cells with specific genetic changes. The trial aims to find the safest…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
Desperate cancer patients get early access to promising immunotherapy combo
Disease control AVAILABLEThis program provides early access to two experimental immunotherapy drugs, Botensilimab and Balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have trie…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug GI-108 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is designed to help the immune system fight cancer. The trial has two parts: first, finding the safest dose, and then seeing if it shrinks tumors. Abo…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New drug JYP0015 targets Hard-to-Treat RAS-Mutant cancers
Disease control Recruiting nowThis study tests an experimental drug called JYP0015 in adults with advanced solid tumors (pancreatic, lung, or colorectal cancer) that have a specific genetic change called a RAS mutation. The goal is to see if the drug is safe and can shrink tumors. About 210 people will take p…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New hope for Hard-to-Treat cancers: experimental drug enters human trials
Disease control Recruiting nowThis study tests an experimental drug, BMS-986523, alone or with other cancer treatments, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard therapy. The main goals are to check safety and find the right dose. About 2…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New pill aims to stop lung cancer relapse in patients with rare gene fusion
Disease control Recruiting nowThis study tests whether the drug taletrectinib can prevent lung cancer from returning in people with a specific gene change (ROS1 fusion) after their tumor has been surgically removed. About 180 adults with stage IB to IIIA non-small cell lung cancer will receive either taletrec…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Personalized cell therapy takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment using donor immune cells (CAR-NK cells) that are specially designed to attack cancer. Up to 85 adults with advanced solid tumors that have not responded to standard therapy will receive cells targeting one or two specific markers found…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 15, 2026 19:01 UTC
-
New combo therapy aims to extend life in advanced lung cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. The study enrolls about 614 adults whose tumors have high PD-L1 lev…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New drug combo aims to control advanced cancers
Disease control Recruiting nowThis early-phase study tests a new drug called LB-LR1109 in people with advanced solid tumors like lung, kidney, head and neck, bladder, or skin cancer that has not responded to standard treatments. The study first gives the drug alone, then in combination with another cancer dru…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: LG Chem • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for lung cancer relapse: combo therapy targets resistant tumors
Disease control Recruiting nowThis study tests whether a new drug combination can help people with stage III lung cancer whose disease has returned after standard treatment. Participants first receive targeted radiation, then two drugs (durvalumab and ceralasertib) to boost the immune system and block cancer …
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New drug KO-2806 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called KO-2806 in about 300 adults with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with other cancer medicines. The main goals are to check safety and see if the drug can shrink tumors.
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
New cancer drug NX-1607 enters first human trials for advanced tumors
Disease control Recruiting nowThis early-stage study tests a new oral drug, NX-1607, in adults with advanced cancers that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 345 participants with various solid tumors or lymphomas will take pa…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New hope for Hard-to-Treat cancers: GTAEXS617 enters human trials
Disease control Recruiting nowThis study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New drug STRO-004 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called STRO-004 in adults with advanced solid tumors that have not responded to other treatments. The trial has three parts: finding a safe dose of STRO-004 alone, testing that dose in more people, and combining STRO-004 with another drug (pe…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New lung cancer drug faces off against standard therapy in major trial
Disease control Recruiting nowThis phase 3 study compares a new drug called pumitamig to the current standard drug durvalumab in people with stage III lung cancer that cannot be removed by surgery. Participants must have completed chemotherapy and radiation without their cancer getting worse. The trial will m…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
New hope for hard-to-treat lung cancer: combo drug trial launches
Disease control Recruiting nowThis study tests a new drug (WSD0922-FU) combined with an existing targeted therapy (osimertinib) for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations). The goal is to see if the combination is safe and can shrink tumors. About 48 …
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Wayshine Biopharm, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:29 UTC
-
New drug shows promise in lung cancer trial
Disease control Recruiting nowThis study tests a new drug called Rina-S in about 240 people with advanced non-small cell lung cancer. The goal is to see if the drug can shrink tumors or slow cancer growth. All participants receive the active drug, and treatment may continue as long as it helps and side effect…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 10, 2026 13:29 UTC
-
New drug IDE574 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called IDE574 in people with advanced solid tumors or a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study has two parts: first, testing IDE574 alone in various cancers; second, combining it…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC
-
Could a leukemia drug help lung cancer patients Who've run out of options?
Disease control Recruiting nowThis early-phase study tests gilteritinib, a drug already approved for a type of leukemia, in about 40 adults with advanced ALK-positive non-small cell lung cancer whose cancer has stopped responding to standard ALK inhibitors. The main goal is to check the drug's safety and tole…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:26 UTC
-
New hope for advanced lung cancer: targeted drug Dato-DXd takes on chemo in major trial
Disease control Recruiting nowThis study compares a new drug, datopotamab deruxtecan (Dato-DXd), against standard chemotherapy (docetaxel) in 400 adults with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated. The cancer must have a specific protein called TROP2 and n…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 10, 2026 13:26 UTC
-
New hope for Hard-to-Treat cancers: experimental drug MT-4561 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have already tried at least one other treatment. The main goals are to find a safe dose and see if the drug can shrink tumors. About 27 adults w…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New combo therapy targets hard-to-treat cancers with RAS mutations
Disease control Recruiting nowThis study tests whether combining RAS(ON) inhibitors with ivonescimab (and possibly other drugs) is safe and effective for adults with advanced or metastatic solid tumors that have a RAS mutation. About 370 participants will receive the treatment to check for side effects, drug …
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New hope for Hard-to-Treat cancers: targeted drug trial opens
Disease control Recruiting nowThis study tests a new drug called RMC-5127, alone or with other medicines, in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific KRAS G12V mutation. The goal is to see if the drug is safe and can shrink tumors. About 574 particip…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:18 UTC
-
Inhaled mist could boost lung cancer treatment before surgery
Disease control Recruiting nowThis study is for people with early-stage non-small cell lung cancer that can be removed with surgery. Researchers want to see if adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy can help kill more cancer cells before surgery. The trial wi…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC
-
New hope for Hard-to-Treat lung cancer: targeted drug combo trial launches
Disease control Recruiting nowThis study is testing new drugs called RAS(ON) inhibitors for people with advanced non-small cell lung cancer that has a RAS mutation. The goal is to see if these drugs are safe and can shrink tumors or slow the cancer's growth. About 616 adults who have already tried standard tr…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC
-
Lung cancer drug safety checked in 500 patients
Disease control Recruiting nowThis study tracks side effects, especially lung problems, in 500 Japanese people with a specific type of non-small cell lung cancer taking Brigatinib. Doctors will monitor participants for 1 year as they receive standard treatment. The goal is to better understand the drug's safe…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Takeda • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
New hope for hard-to-treat lung cancer: targeted pill plus chemo takes on immunotherapy in major trial
Disease control Recruiting nowThis study compares two first-line treatments for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and no PD-L1 protein. One group gets the targeted pill sotorasib plus chemotherapy; the other gets the immunotherapy pembrolizumab plus chemoth…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New PET tracers could sharpen cancer detection
Diagnosis Recruiting nowThis early-phase study is testing two new radioactive imaging agents (JFI447 and FFG233) to see how well they light up different solid tumors on PET scans. About 66 adults with advanced cancers like pancreatic, lung, breast, colorectal, or sarcoma will receive the agents and unde…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 15, 2026 19:07 UTC
-
Glow-in-the-Dark dye could help surgeons remove lung cancer more completely
Diagnosis Recruiting nowThis study tests a special dye called LS301-IT that makes lung cancer cells glow during surgery. About 35 adults with early-stage non-small cell lung cancer will receive the dye before their tumor-removal surgery. The goal is to see if the dye helps surgeons find and remove all c…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Integro Theranostics • Aim: Diagnosis
Last updated Jun 12, 2026 12:04 UTC
-
Deep-Breathing device may shield lung cancer patients from radiation side effects
Symptom relief Recruiting nowThis study tests whether using an incentive spirometer—a device that encourages deep breathing—can lower the risk of lung inflammation (pneumonitis) in people with advanced lung cancer receiving chemotherapy and radiation. About 100 participants will use the device 10 times every…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: NA • Sponsor: The Cooper Health System • Aim: Symptom relief
Last updated Jun 15, 2026 19:07 UTC
-
Lung cancer drug under the microscope: Real-World study launches
Knowledge-focused Recruiting nowThis study is observing 240 lung cancer patients in Germany and Austria who are receiving the drug tislelizumab as part of their normal care. Researchers want to see how long patients live, how they feel, and what side effects occur. The goal is to learn how well the drug works o…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:48 UTC
-
New imaging agent RAD301 tested in tiny study for pancreatic and other cancers
Knowledge-focused Recruiting nowThis early-stage study is testing a new imaging agent called RAD301 in 9 people: healthy volunteers and patients with certain cancers like pancreatic, lung, or ovarian cancer. The goal is to see how the body handles the radiation from RAD301 and whether it is safe. No treatment i…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:08 UTC
-
Lung wash may spare cancer patients painful biopsies
Knowledge-focused Recruiting nowThis study explores whether genetic material (DNA and RNA) from tiny particles called extracellular vesicles, collected during a routine lung wash (bronchoalveolar lavage), can be used for genetic testing in people with advanced non-small cell lung cancer. The goal is to see if t…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: NA • Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:02 UTC
-
Real-World data: does adding immunotherapy before lung surgery improve outcomes?
Knowledge-focused Recruiting nowThis study reviews medical records of 100 adults in Taiwan with resectable non-small cell lung cancer who received nivolumab (an immunotherapy) combined with chemotherapy before surgery. Researchers want to see if this approach helps shrink tumors completely and delays cancer ret…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:01 UTC
-
Lung cancer study asks: what do patients and doctors really want from treatment?
Knowledge-focused Recruiting nowThis study interviews 55 people — patients with early-stage non-small cell lung cancer and their doctors — to understand their views on treatment options. No new drugs are tested. The goal is to learn what matters most to patients and physicians when choosing a treatment plan.…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:03 UTC
-
New study tracks how a targeted drug combo fights lung cancer in everyday care
Knowledge-focused Recruiting nowThis study watches 100 adults with metastatic non-small cell lung cancer who have certain EGFR gene changes and are already getting amivantamab plus chemotherapy through an early access program. Researchers want to see how long the cancer stays under control in real-world setting…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: GFPC Investigation • Aim: Knowledge-focused
Last updated Jun 11, 2026 12:09 UTC